# ORIGIN 3

Type: clinical_trial

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/origin-3
Canonical HTML page: https://gethealthbrief.com/entity/origin-3

## Recent coverage (1 stories)

### 42% Proteinuria Cut: FDA Backs Vera’s IgAN Drug with Accelerated Approval
2026-07-12 07:12:03 · Sentiment: Positive · Impact: 8/10 · Sources: 2

The FDA’s accelerated approval of TRUTAKNA marks the first BAFF/APRIL inhibitor for IgA nephropathy, showing a 42% UPCR reduction over placebo. Healthcare providers now have a therapy targeting upstream disease drivers, with launch imminent and a confirmatory trial ongoing.
Full story: https://gethealthbrief.com/story/trutakna-accelerated-approval-iga-nephropathy-health

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.